Healthcare / BiotechnologyShanghai
$19.46
-0.50 (-2.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $71.4M · quality 41.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.9B
P/E
20.3x
↑EV/EBITDA
12.0x
↓ROE
16.9%
↑Gross Margin
59.7%
↑Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.0%
FCF CAGR
—
FCF margin
4.2%
FCF / Net income
0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.70B · net income $449.2M · FCF $71.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.70B | $1.70B | $1.48B | $1.26B | $1.01B |
| Net Income | $449.2M | $449.2M | $354.8M | $289.4M | $211.0M |
| EBITDA | $679.0M | $679.0M | $511.5M | $410.9M | $311.0M |
| EPS | 1.10 | 1.10 | 0.89 | 0.71 | 0.52 |
| Gross Margin | 59.7% | 59.7% | 58.6% | 55.9% | 51.6% |
| Operating Margin | 33.0% | 33.0% | 27.9% | 23.5% | 22.7% |
| Net Margin | 26.5% | 26.5% | 24.0% | 22.9% | 20.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.41 | 0.06 | 0.03 |
| Current Ratio | 4.22 | 4.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $71.4M | $71.4M | $-207.9M | $80.1M | $-49.8M |
| Returns | |||||
| ROE | 16.9% | 16.9% | 15.2% | 14.7% | 12.6% |
| Valuation | |||||
| P/E | 20.27 | 20.27 | 22.81 | 35.79 | 47.37 |
| EV/EBITDA | 11.98 | 11.98 | 16.17 | 24.16 | 31.04 |
| P/B | 2.99 | 2.99 | 3.47 | 5.26 | 5.96 |
| Growth & Yield | |||||
| Revenue Growth | 15.0% | 15.0% | 16.9% | 25.2% | — |
| EPS Growth | 23.6% | 23.6% | 25.4% | 36.5% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
16.2%
EPS terminal req.
$1.73
Spread vs growth
7.4%
5Y implied EPS CAGR
13.7%
EPS terminal req.
$2.09
Spread vs growth
9.9%
10Y implied EPS CAGR
11.8%
EPS terminal req.
$3.36
Spread vs growth
11.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.6%
Start / end P/E
24.3x → 17.7x
EPS bridge
0.89 → 1.10
Residual
-6.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.